MOR vs. SRPT, QGEN, PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, and LEGN
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.
MorphoSys vs.
Sarepta Therapeutics (NASDAQ:SRPT) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.
Sarepta Therapeutics currently has a consensus price target of $178.71, suggesting a potential upside of 51.45%. MorphoSys has a consensus price target of $18.25, suggesting a potential downside of 3.74%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than MorphoSys.
Sarepta Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
In the previous week, Sarepta Therapeutics had 29 more articles in the media than MorphoSys. MarketBeat recorded 29 mentions for Sarepta Therapeutics and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.95 beat Sarepta Therapeutics' score of 0.72 indicating that MorphoSys is being referred to more favorably in the news media.
Sarepta Therapeutics has a net margin of 7.43% compared to MorphoSys' net margin of -226.79%. Sarepta Therapeutics' return on equity of 11.00% beat MorphoSys' return on equity.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Sarepta Therapeutics received 1438 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 75.33% of users gave Sarepta Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
MorphoSys has lower revenue, but higher earnings than Sarepta Therapeutics. MorphoSys is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Sarepta Therapeutics beats MorphoSys on 15 of the 19 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
This page (NASDAQ:MOR) was last updated on 1/20/2025 by MarketBeat.com Staff
Free MOR Stock Alerts